<SEC-DOCUMENT>0001370053-21-000018.txt : 20210225
<SEC-HEADER>0001370053-21-000018.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225160906
ACCESSION NUMBER:		0001370053-21-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO, INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37985
		FILM NUMBER:		21680345

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYSBIO INC
		DATE OF NAME CHANGE:	20080828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>anab-20210225.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194,d:26f185504a3b44cfb7093400fe3d60e4--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>anab-20210225</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF80L2ZyYWc6ODQ5NDgyY2VjNWIyNDRmMDk4YzkxYjlmNGU3YWMyNzAvdGFibGU6ODgxMzA5ZWEyZDNlNDFlMzgzZjEwNDY1YmNjNjViMmIvdGFibGVyYW5nZTo4ODEzMDllYTJkM2U0MWUzODNmMTA0NjViY2M2NWIyYl8yLTEtMS0xLTA_a6e6c7bd-0b89-4390-97ba-5f39eb8cdfb9">0001370053</ix:nonNumeric><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF80L2ZyYWc6ODQ5NDgyY2VjNWIyNDRmMDk4YzkxYjlmNGU3YWMyNzAvdGFibGU6ODgxMzA5ZWEyZDNlNDFlMzgzZjEwNDY1YmNjNjViMmIvdGFibGVyYW5nZTo4ODEzMDllYTJkM2U0MWUzODNmMTA0NjViY2M2NWIyYl81LTEtMS0xLTA_41c12821-ea31-42a1-9ace-cc0ec61a61d0">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="anab-20210225.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-25</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26f185504a3b44cfb7093400fe3d60e4_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY1_e424a5c6-3780-4eea-a653-2466dd179cd6">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT TO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report: <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xOTE_9b1e0fab-4b2d-4e0c-bbf3-dc017e9f50c1">February 25, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU4_cd4fcb52-9330-4d65-9160-adfa69301dc0">ANAPTYSBIO, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.857%"><tr><td style="width:1.0%"></td><td style="width:33.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTAtMS0xLTA_644a96e8-ef31-4ae4-ae4f-9f7a0bcd6be1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTEtMS0xLTA_25869e7a-9471-4b0b-9bc4-6dda379ddc73">001-37985</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTItMS0xLTA_7446d927-1f8c-43e0-bdda-272968c9392f">20-3828755</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU5_b8793b52-1fab-4589-a150-6ac5ff775e30">10421 Pacific Center Court</ix:nonNumeric>, <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY2_af5a7ef8-9826-425a-95d6-d10487b06dd1">Suite 200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYy_df16f606-5112-47cc-95b3-661ff3cc79b4">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY3_0846de89-adc6-407f-80d9-c4ab1014f0ef">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYz_f22b22f6-4558-4621-bebe-2832d438b0e8">92121</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, and Zip Code)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY4_16ece970-f671-4db4-ad98-eb63ed18afcb">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY0_071ea41c-5afb-4eb6-890e-e4180b8a55e2">362-6295</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8&#8209;K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYw_6fd48a74-de58-457f-8c9b-d975b51886dc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY5_9a4f46d6-3115-401f-acc6-6b434ac55c95">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a&#8209;12 under the Exchange Act (17 CFR 240.14a&#8209;12)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU2_cc78e335-ccf5-41a6-9ec2-202f6bd57a82">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre&#8209;commencement communications pursuant to Rule&#160;14d&#8209;2(b)&#160;under the Exchange Act (17 CFR 240.14d&#8209;2(b))</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzcw_5efb72a1-a622-42cc-909d-24a8df9598db">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre&#8209;commencement communications pursuant to Rule&#160;13e&#8209;4(c)&#160;under the Exchange Act (17 CFR 240.13e&#8209;4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:35.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTAtMS0xLTA_6be2672d-6614-43a4-b250-90755ce1680e">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTEtMS0xLTA_67ec8e25-099d-44ba-878b-8dffac72d78d">ANAB</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTItMS0xLTA_799a9735-fa17-4e0d-b280-c8828a29a9f6">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYx_c1d52648-7fa9-423b-a20d-71cf7f572838">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i26f185504a3b44cfb7093400fe3d60e4_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On February 25, 2021, AnaptysBio, Inc. (&#8220;AnaptysBio&#8221;) issued a press release announcing its financial results for the three months and year ended December 31, 2020. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Item 9.01. &#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d) Exhibits</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit Title or Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="q42020earningsrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Press release issued by AnaptysBio, Inc. regarding its financial results for the three months and year ended December 31, 2020, dated February 25, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).</span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AnaptysBio, Inc.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  February 25, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Dennis Mulroy</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name: Dennis Mulroy</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q42020earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i43a8a21cce6149b385eed44488c5bf32_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:174%">AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provides Pipeline Updates</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated in mid-2021    </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmoplantar pustulosis (PPP) anticipated in Q1 2021</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Expansion of imsidolimab program into four additional dermatological inflammatory Phase 2 clinical trials, including EGFRi-mediated skin toxicities, ichthyosis, hidradenitis suppurativa and acne, with top-line data readouts from Phase 2 trials anticipated through 2021 and 2022</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advancement of ANB030 into a healthy volunteer Phase 1 trial with top-line data anticipated in mid-2021 and initiation of Phase 2 clinical trials in alopecia areata and vitiligo in Q4 2021</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Amended strategic immuno-oncology collaboration with GlaxoSmithKline (GSK) to increase dostarlimab royalties to 8-25% of global sales, add 1% Zejula</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> royalty effective January 2021 and receive additional $60 million cash in Q4 2020</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">$75MM in cash milestones anticipated from dostarlimab regulatory milestones under GSK collaboration over upcoming 18 months, including US BLA and EU MAA approval for dMMR endometrial cancer anticipated in H1 2021 and acceptance of US BLA for pan-dMMR tumors in Q1 2021 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SAN DIEGO, February 25, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> - AnaptysBio, Inc. (Nasdaq&#58; ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the fourth quarter and year ended December 31, 2020 and provided pipeline updates.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;We made progress in advancing AnaptysBio&#8217;s pipeline during 2020 and look forward to multiple clinical readouts from our wholly-owned programs in 2021.  Imsidolimab will continue to be our key focus going forward as we anticipate GPP Phase 3 initiation and Phase 2 topline readouts from five other immune-dermatology indications through 2021 and 2022.  We also anticipate commercial launch of dostarlimab this year and meaningful milestone and royalty revenue to AnaptysBio under our GSK partnership,&#8221; said Hamza Suria, president and chief executive officer of AnaptysBio. &#8220;Our strategy is to continue advancing first-in-class immunology-focused therapeutic antibodies through key clinical data catalysts using a capital-efficient business model.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Imsidolimab (Anti-IL-36 Receptor) Program</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">In July, we announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, our proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">In October, we announced positive topline data from an interim analysis of our imsidolimab GALLOP Phase 2 trial in GPP.  Six of 8 patients achieved the primary endpoint of disease improvement upon Day 29, while erythema with skin pustules, which clinically defines GPP, decreased by 94% on Day 29 relative to baseline.  We plan to report 16-week data from the GALLOP trial at a medical conference in 2021.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">We anticipate initiation of a Phase 3 trial for imsidolimab in GPP during mid-2021 following completion of protocol alignment, and review of 16-week data from the Phase 2 GALLOP trial, with the FDA.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">We are also conducting a randomized, placebo-controlled, multi-dose Phase 2 trial in 59 patients with palmoplantar pustulosis, or PPP, also known as the POPLAR trial, with topline data anticipated in Q1 2021. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">We have expanded our imsidolimab program into third and fourth new clinical indications, EGFRi-mediated skin toxicities and ichthyosis, with interim top-line data from Phase 2 trials anticipated at the end of 2021 and in 2022, respectively, and we are also expanding the imsidolimab program into fifth and sixth </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">new clinical indications, hidradenitis suppurativa and acne, with initiation of Phase 2 trials in these indications anticipated in Q2 2021.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">We initiated a worldwide registry of GPP and PPP patients, named RADIANCE, in Q1 2021, to improve understanding of the patient journey and support enrollment of future trials.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANB030 (Anti-PD-1 Agonist) Program</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">We anticipate topline data from our ongoing Phase 1 healthy volunteer clinical trial of ANB030, our wholly-owned PD-1 agonist antibody, designed to assess the safety, pharmacokinetics and pharmacodynamics of ANB030 in single and multiple ascending dose cohorts in mid-2021.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Preclinical translational data using ANB030 was presented in March 2020 at the Festival of Biologics Meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%;padding-left:13.8pt">We anticipate initiating Phase 2 trials of ANB030 in alopecia areata and vitiligo in Q4 2021.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANB032 (Anti-BTLA Modulator) Program</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">We filed a Clinical Trial Notification (&#8220;CTN&#8221;) in Australia for ANB032, our wholly-owned BTLA modulator antibody, during the first quarter of 2021 and anticipate initiating a healthy volunteer Phase 1 trial in the first half of 2021 upon clearance of the CTN. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">We presented preclinical data regarding ANB032 at the 2020 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting in October 2020.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Etokimab (ANB020 Anti-IL-33) Program</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">We discontinued further development of etokimab, our anti-IL-33 antibody previously referred to as ANB020, following review of topline week 16 data from the approximately 100-patient ECLIPSE trial in chronic rhinosinusitis with nasal polyps (CRSwNP), where patients dosed with etokimab every four (q4w) or eight weeks (q8w) failed to achieve statistically significant over placebo on either co-primary endpoint.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dostarlimab (Anti-PD-1 Antagonist) Program Partnered with GSK</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">In October 2020, we amended our immuno-oncology collaboration with GSK resulting in increased financial consideration to AnaptysBio. Royalties due to AnaptysBio for dostarlimab were increased to 8-25% of global net sales, where AnaptysBio will receive 8% of annual global net sales below $1 billion, and 12-25% of net sales above $1 billion. The $1.1 billion in cash milestone payments due under the collaboration agreement remain unchanged, and AnaptysBio anticipates receiving $75 million in such cash milestones over the next 18 months as dostarlimab obtains FDA and EMA regulatory approval for the first two indications. An additional $165 million in sales milestones is anticipated by AnaptysBio upon achievement of certain dostarlimab annual sales revenues. GSK also agreed, starting January 1, 2021, to pay AnaptysBio a 1% royalty on all of GSK&#8217;s global net sales of Zejula. In addition, GSK paid AnaptysBio a one-time cash payment of $60 million in Q4 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In exchange, AnaptysBio provided GSK with freedom to conduct development and commercialization of Zejula in combination with third-party molecules and settled the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">dispute between AnaptysBio and GSK.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">US BLA and European Union EMA approvals for dostarlimab are anticipated for endometrial cancer in H1 2021, which will result in $20 million and $10 million milestone payments, respectively.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The FDA recently accepted a subsequent US BLA for dostarlimab in pan-deficient mismatch repair tumors and we anticipate receiving a $10 million payment from GSK in Q1 2021 as a result of this milestone.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">In January 2021, the Company appointed Dr. Magda Marquet to its board of directors. She is the co-founder of AltheaDx, a commercial stage, precision medicine company, and co-founded Althea Technologies and as its co-CEO led the company to become a highly profitable, commercial company. Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals.  She currently serves on the Board of Directors of Arcturus Therapeutics, Micronoma, Matrisys Biosciences and ProciseDx.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fourth Quarter Financial Results</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%;padding-left:13.8pt">Cash, cash equivalents and investments totaled $411.2 million as of December&#160;31, 2020 compared to $428.5 million as of December&#160;31, 2019, for a net decrease of $17.3 million. The decrease relates primarily to cash used for operating activities partially offset by an increase in collaboration revenue of $67.0 million. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">Collaboration revenue was $60.0 million and $75.0 million for the three and twelve months ended December&#160;31, 2020, which related to milestone payments for successful BLA and MAA filings for dostarlimab and the $60.0 million amendment related payment from GSK, compared to $3.0 million and $8.0 million for the three and twelve months ended December&#160;31, 2019. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt">Research and development expenses were $21.6 million and $80.0 million for the three and twelve months ended December&#160;31, 2020, compared to $21.4 million and $99.3 million for the three and twelve months ended December&#160;31, 2019. The annual decrease was due primarily to reduced outside services for manufacturing and clinical activities based on the timing of projects.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%;padding-left:13.8pt">General and administrative expenses were $5.1 million and $18.9 million for the three and twelve months ended December&#160;31, 2020, compared to $3.8 million and $16.1 million for the three and twelve months ended December&#160;31, 2019. The increase was due primarily to increased legal and insurance expenses. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Net income was $33.6 million for the three months ended December&#160;31, 2020, or a net income per share of $1.23 and a net loss of $19.9 million for the twelve months ended December&#160;31, 2020, or a net loss per share of $0.73, compared to a net loss of $20.3 million and $97.3 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">for the three and twelve months ended December&#160;31, 2019, or a net loss per share of $0.75 and $3.60.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Guidance</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">AnaptysBio expects its net cash burn in 2021 will be close to $100 million. We anticipate that our cash, cash equivalents and anticipated revenues will fund our current operating plan at least into 2024.</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About AnaptysBio</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company&#8217;s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi, ichthyosis, hidradenitis suppurativa and acne&#59; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated&#59; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio&#8217;s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This press release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to&#58; the timing of the release of data from our clinical trials, including imsidolimab&#8217;s Phase 2 clinical trial in PPP, imsidolimab&#8217;s Phase 2 clinical trials in EGFRi, ichthyosis, hidradenitis suppurativa, and acne, and ANB030&#8217;s Phase 1 healthy volunteer clinical trial&#59; the timing of initiation of imsidolimab&#8217;s Phase 2 clinical trials in hidradenitis suppurativa and acne&#59; the timing of initiation of imsidolimab&#8217;s Phase 3 clinical trial in GPP&#59; the timing of initiation of ANB032&#8217;s Phase 1 healthy volunteer clinical trial&#59; the milestones and royalty payments to be received under the GSK collaboration&#59; and our projected 2021 cash burn and cash runway. Statements including words such as &#8220;plan,&#8221; &#8220;continue,&#8221; &#8220;expect,&#8221; or &#8220;ongoing&#8221; and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company&#8217;s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company&#8217;s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company&#8217;s ability to fund development activities and achieve development goals, the company&#8217;s ability to protect intellectual property and other risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dennis Mulroy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AnaptysBio, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">858.732.0201</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">dmulroy&#64;anaptysbio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,017&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,197&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,210&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,908&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,506&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,561&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377,733&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,481&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,552&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,197&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,237&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,052&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable, current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,821&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2020 and December 31, 2019, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.001 par value, 500,000 shares authorized, 27,356 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">shares and 27,255 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660,665&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">648,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263,957)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(244,026)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,731&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405,008&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,552&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,197&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,567&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,426&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,088&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,854&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,094&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,655&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,258&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,879&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,432&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,345&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,258)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,879)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,432)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,041)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,282&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,959&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,984&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,944&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,646&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,285)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,931)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,488)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,646&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,263)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,931)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,336)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) income on available for sale securities, net of tax of $0, ($36), $0, and $153, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(342)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,383&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,405)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,273)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,775)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.75)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.73)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.60)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.75)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.73)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.60)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,349&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,938&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,154&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,302&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,059&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>anab-20210225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:anab="http://www.anaptysbio.com/20210225" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anaptysbio.com/20210225">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210225_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210225_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.anaptysbio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>anab-20210225_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20210225.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>anab-20210225_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20210225.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended" id="i92bb6392175e42fba1337fe7c22d5e34_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_df5f533c-e44e-4868-bc1b-893b1d150717" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:to="loc_dei_DocumentType_df5f533c-e44e-4868-bc1b-893b1d150717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_49821669-45d9-4370-b6dc-e28622d17fd4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:to="loc_dei_DocumentInformationTable_49821669-45d9-4370-b6dc-e28622d17fd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>anab-20210225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_480ebee8-d46b-4141-8ab6-af5302894891_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_66fa8084-fa1a-4bf5-9dfc-1d2473959115_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1ded43cd-1def-44fc-b769-fc3d479a27c0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9086104b-fd53-48f4-82e9-90fbc36f1f37_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_85a1074d-8870-47e4-8e68-c4f4703132e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b18e4c43-b344-4541-9d4e-cb7d3c31743e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4cf2315f-e730-4745-8b78-3d95cb358237_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b827f87e-4583-43cd-88cf-3bde703410c6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_39b87ab3-dae3-4613-8e54-04a350e5f828_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b832d2aa-6420-4ade-bd4d-15d9533f834b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_820e0f2e-e470-4bcd-b8ba-39aac9665deb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7583100c-1f61-4826-bab8-c82b991a5fa0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f4d9cabd-6da7-4b94-b3ff-2d31c9a17238_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a28c6623-1da0-44d0-b2a6-fdcfc0ff475d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d7353212-13a5-4002-987e-d97190e28cfe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_935b1b54-5db4-4f4b-a6f5-14cf2d691729_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_492727e6-95da-4d07-aadb-7a831eac740a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_520e8ec3-ae27-41fb-98e4-b166db0c9621_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f52ecfaa-bf96-4a4a-aa52-43ffe144d6f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e04eb198-729c-4845-815c-d78304469985_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e04544d9-fabc-4390-8717-2dcc39099a02_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5e167b71-0308-46b1-9d07-5c9f4383f744_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_4bd6c45e-338d-4860-872b-ae60e8919605_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_78bd145e-4148-44b8-9e69-b5ed91b1afc7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_baf52abc-107e-4f9e-9b95-e1c5fdf717f2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_ef870bc5-de02-489b-b951-d31f31f7e13d_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>anab-20210225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9263a9c7-345d-4fad-8c52-e33bbf13cd03,g:1f9842e3-070f-468f-909d-cd4a340ad194-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20210225.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aad97994-63e0-457b-983c-c10865635285" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_DocumentType_aad97994-63e0-457b-983c-c10865635285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_35968f3f-15aa-4865-afef-3f42d2f9dbcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_DocumentPeriodEndDate_35968f3f-15aa-4865-afef-3f42d2f9dbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6462a0e1-9e99-41a7-a63c-29a5af1ee9ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityRegistrantName_6462a0e1-9e99-41a7-a63c-29a5af1ee9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7c275ae9-3c03-4597-820c-1dc4e7ff1b4b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7c275ae9-3c03-4597-820c-1dc4e7ff1b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c97aba42-e51c-414e-b216-f685ba25d600" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityFileNumber_c97aba42-e51c-414e-b216-f685ba25d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_59eac727-f6ff-439d-aec7-ab13400c39b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityTaxIdentificationNumber_59eac727-f6ff-439d-aec7-ab13400c39b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_01bf1a23-c786-406d-8162-b07c7149b049" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityAddressAddressLine1_01bf1a23-c786-406d-8162-b07c7149b049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9848f5f6-3b55-45f7-99ab-ff520c2f15ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityAddressAddressLine2_9848f5f6-3b55-45f7-99ab-ff520c2f15ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9a4a981d-5bf2-4bb9-ac34-fb90b3afc16d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityAddressCityOrTown_9a4a981d-5bf2-4bb9-ac34-fb90b3afc16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1f4bd7c6-028b-44f9-8cdd-253f26b93d0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityAddressStateOrProvince_1f4bd7c6-028b-44f9-8cdd-253f26b93d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4d5172cb-36b4-451a-8e19-2c3ffe453d94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityAddressPostalZipCode_4d5172cb-36b4-451a-8e19-2c3ffe453d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_acecbf9f-0c6c-4518-a4fd-5792ab068526" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_CityAreaCode_acecbf9f-0c6c-4518-a4fd-5792ab068526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_730f6cb0-bc93-4f7a-a5d2-137531d2c6c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_LocalPhoneNumber_730f6cb0-bc93-4f7a-a5d2-137531d2c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_50681a6a-fcc2-4021-9f45-22e448134fa2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_WrittenCommunications_50681a6a-fcc2-4021-9f45-22e448134fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_742b5873-5dec-4792-ac51-1ab49bb8fa6b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_SolicitingMaterial_742b5873-5dec-4792-ac51-1ab49bb8fa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6c049235-0ca6-474d-8091-9c88e176e4a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_PreCommencementTenderOffer_6c049235-0ca6-474d-8091-9c88e176e4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_831d03b1-f921-4936-b1bc-df1d9c7195b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_831d03b1-f921-4936-b1bc-df1d9c7195b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a56fcb59-8683-4413-bb17-77f96cfe1684" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_Security12bTitle_a56fcb59-8683-4413-bb17-77f96cfe1684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d95f114d-963b-4151-a8be-22942a36d614" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_TradingSymbol_d95f114d-963b-4151-a8be-22942a36d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_82d6a21a-b099-45b6-96a9-349ddfb417c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_SecurityExchangeName_82d6a21a-b099-45b6-96a9-349ddfb417c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a0d29f6-b685-4cff-bf9f-f76386c55174" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a0d29f6-b685-4cff-bf9f-f76386c55174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8b3b980e-8bee-4ccf-9ec2-1f6497d1a60b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_EntityCentralIndexKey_8b3b980e-8bee-4ccf-9ec2-1f6497d1a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_443bb827-84f1-4be9-b74a-fbee6a665045" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_AmendmentFlag_443bb827-84f1-4be9-b74a-fbee6a665045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_49821669-45d9-4370-b6dc-e28622d17fd4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a9f2818-96ca-40aa-919f-b96f84777279" xlink:to="loc_dei_DocumentInformationTable_49821669-45d9-4370-b6dc-e28622d17fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_49821669-45d9-4370-b6dc-e28622d17fd4" xlink:to="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_df5f533c-e44e-4868-bc1b-893b1d150717" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bc32f17b-6bd6-4098-abf3-37f837c5615c" xlink:to="loc_dei_DocumentType_df5f533c-e44e-4868-bc1b-893b1d150717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>anab-20210225_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anab-20210225.xsd" xlink:type="simple"/>
    <context id="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF80L2ZyYWc6ODQ5NDgyY2VjNWIyNDRmMDk4YzkxYjlmNGU3YWMyNzAvdGFibGU6ODgxMzA5ZWEyZDNlNDFlMzgzZjEwNDY1YmNjNjViMmIvdGFibGVyYW5nZTo4ODEzMDllYTJkM2U0MWUzODNmMTA0NjViY2M2NWIyYl8yLTEtMS0xLTA_a6e6c7bd-0b89-4390-97ba-5f39eb8cdfb9">0001370053</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF80L2ZyYWc6ODQ5NDgyY2VjNWIyNDRmMDk4YzkxYjlmNGU3YWMyNzAvdGFibGU6ODgxMzA5ZWEyZDNlNDFlMzgzZjEwNDY1YmNjNjViMmIvdGFibGVyYW5nZTo4ODEzMDllYTJkM2U0MWUzODNmMTA0NjViY2M2NWIyYl81LTEtMS0xLTA_41c12821-ea31-42a1-9ace-cc0ec61a61d0">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY1_e424a5c6-3780-4eea-a653-2466dd179cd6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xOTE_9b1e0fab-4b2d-4e0c-bbf3-dc017e9f50c1">2021-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU4_cd4fcb52-9330-4d65-9160-adfa69301dc0">ANAPTYSBIO, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTAtMS0xLTA_644a96e8-ef31-4ae4-ae4f-9f7a0bcd6be1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTEtMS0xLTA_25869e7a-9471-4b0b-9bc4-6dda379ddc73">001-37985</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6ODI1N2U1YzFlOTA0NGJiZWJjM2IwOTIxMDgwODRkYWIvdGFibGVyYW5nZTo4MjU3ZTVjMWU5MDQ0YmJlYmMzYjA5MjEwODA4NGRhYl8wLTItMS0xLTA_7446d927-1f8c-43e0-bdda-272968c9392f">20-3828755</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU5_b8793b52-1fab-4589-a150-6ac5ff775e30">10421 Pacific Center Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY2_af5a7ef8-9826-425a-95d6-d10487b06dd1">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYy_df16f606-5112-47cc-95b3-661ff3cc79b4">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY3_0846de89-adc6-407f-80d9-c4ab1014f0ef">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYz_f22b22f6-4558-4621-bebe-2832d438b0e8">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY4_16ece970-f671-4db4-ad98-eb63ed18afcb">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY0_071ea41c-5afb-4eb6-890e-e4180b8a55e2">362-6295</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYw_6fd48a74-de58-457f-8c9b-d975b51886dc">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzY5_9a4f46d6-3115-401f-acc6-6b434ac55c95">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzU2_cc78e335-ccf5-41a6-9ec2-202f6bd57a82">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzcw_5efb72a1-a622-42cc-909d-24a8df9598db">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTAtMS0xLTA_6be2672d-6614-43a4-b250-90755ce1680e">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTEtMS0xLTA_67ec8e25-099d-44ba-878b-8dffac72d78d">ANAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGFibGU6MzE0NmFiOTEzMzhmNGFjYmFiNGYwNzcxNmMxYjc2NTIvdGFibGVyYW5nZTozMTQ2YWI5MTMzOGY0YWNiYWI0ZjA3NzE2YzFiNzY1Ml8xLTItMS0xLTA_799a9735-fa17-4e0d-b280-c8828a29a9f6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ZjE4NTUwNGEzYjQ0Y2ZiNzA5MzQwMGZlM2Q2MGU0L3NlYzoyNmYxODU1MDRhM2I0NGNmYjcwOTM0MDBmZTNkNjBlNF8xL2ZyYWc6NTdlOGFmODJmODA1NDhlMzhlZjM5MmZiYjMxODEzNzkvdGV4dHJlZ2lvbjo1N2U4YWY4MmY4MDU0OGUzOGVmMzkyZmJiMzE4MTM3OV8xNzYx_c1d52648-7fa9-423b-a20d-71cf7f572838">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140590001699224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAPTYSBIO, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3828755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10421 Pacific Center Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">362-6295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001370053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_!EJ,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @ (H%94I>*NQS
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M/UY_ 5!+ 0(4 Q0    ( "*!65('04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (H%94B1GX8[O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ (H%94IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  B@5E2&UO=&6X$  #'$0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ (H%94H.II0/4 0  ,@8   T              ( !L@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  B@5E2EXJ[',     3 @  "P
M    @ &Q#@  7W)E;',O+G)E;'-02P$"% ,4    "  B@5E2&445]3<!   G
M @  #P              @ &:#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ (H%94B0>FZ*M    ^ $  !H              ( !_A   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ (H%94F60>9(9 0  SP,
M !,              ( !XQ$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  +1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="anab-20210225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="anab-20210225.htm">anab-20210225.htm</File>
    <File>anab-20210225.xsd</File>
    <File>anab-20210225_cal.xml</File>
    <File>anab-20210225_def.xml</File>
    <File>anab-20210225_lab.xml</File>
    <File>anab-20210225_pre.xml</File>
    <File>q42020earningsrelease.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anab-20210225.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "anab-20210225_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anab-20210225_def.xml"
     ]
    },
    "inline": {
     "local": [
      "anab-20210225.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anab-20210225_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anab-20210225_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "anab-20210225.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "anab",
   "nsuri": "http://www.anaptysbio.com/20210225",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210225.htm",
      "contextRef": "ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.anaptysbio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210225.htm",
      "contextRef": "ie7272d65f37a445ab4586e79bcc315b5_D20210225-20210225",
      "decimals": null,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001370053-21-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370053-21-000018-xbrl.zip
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MEBSC<F4<\YV>[[.'/S^XOH>.GI^<5.11I$*KH[=:_@/1\E>EM_\?4$L#!!0
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MM6P/VK!_TFZ^GYS&7K YZ&>#GU!+ P04    "  B@5E2D;D2$H8!  #6 @
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MS^;>MRS_GOQ@ +RM7G2>W3SDR=5UX05^ +=_F[^B0808%3% .)0 :R8!$6$
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M)V:VI2N=D+6E?@1L:V$'1]>6E U?Z[B>2UKE76*?\LOL+IWJ,%!",P:XIA'
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MFA2V5M7G!5X8)X>1[D.G# %"KZ?DIWM&KS1ZFO<W_XG'.';I7+3:XO^ XHF
MD-J#-3Q H,0HJ;AD1H[@_+<V;_O^[0SOU6%6U3'5N*#<&'5UN#?;MV&^'K$X
M=35>",))L8XW9W<KRQCSUE8CZ'<U.>CN?(91YU37*1Y>S<VCP?61M;C,IG[D
M&/-^E.JBBF_*^ NNPTLN+2Z*/ .5*(! I\'EE(%GP2++-OH01P3@EO%!)+#I
MD_!T15\8B3=E6[27[].JZ)0HV]_=)BV54,R11,$F:T%0I\$I1)I9)UVF*=F4
M1B#B(=N#@.#3!>+9>DZ"AP/,X^K3JNZ%_X#ZI_WJK&SKR_TJIJ4.3$N7+/"
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M+"4\YM!YD0) 2N;T!#QJ 5OB7;8O1ARP$K,1\4K.NH=[ 0X)$D(-+80VRQ7
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MQ?%3"3*9U0(R\.^Y_<+UJ,V0FP""P6;H2$4-!BJRST..ML\$^VB.WQC'_UG
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M-2YH=&U02P$"% ,4    "  B@5E22(\+=(T"  "*"0  $0
M@ &X%   86YA8BTR,#(Q,#(R-2YX<V102P$"% ,4    "  B@5E2D;D2$H8!
M  #6 @  %0              @ %T%P  86YA8BTR,#(Q,#(R-5]C86PN>&UL
M4$L! A0#%     @ (H%94L+FLYH/ P  6 L  !4              ( !+1D
M &%N86(M,C R,3 R,C5?9&5F+GAM;%!+ 0(4 Q0    ( "*!65)7X;?C=0L
M -IJ   5              "  6\<  !A;F%B+3(P,C$P,C(U7VQA8BYX;6Q0
M2P$"% ,4    "  B@5E2(@E<F6\'  #M.0  %0              @ $7*
M86YA8BTR,#(Q,#(R-5]P<F4N>&UL4$L! A0#%     @ (H%94NHQQV8V)
MT<0! !D              ( !N2\  '$T,C R,&5A<FYI;F=S<F5L96%S92YH
8=&U02P4&      < !P#1 0  )E0

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
